Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)‘s stock had its “outperform” rating restated by investment analysts at CIBC in a research report issued on Thursday. They presently have a $7.00 price objective on the biotechnology company’s stock, up from their prior price objective of $4.00. CIBC’s target price suggests a potential upside of 131.02% from the stock’s previous close.

CATB has been the subject of several other research reports. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Oppenheimer Holdings, Inc. cut their price objective on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. HC Wainwright increased their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Citigroup Inc. reiterated a “hold” rating and issued a $1.50 price objective on shares of Catabasis Pharmaceuticals in a research report on Friday, September 29th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $5.75.

Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded down 8.58% during midday trading on Thursday, reaching $2.77. 5,375,874 shares of the company traded hands. Catabasis Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $5.74. The stock’s market capitalization is $62.27 million. The stock’s 50-day moving average is $1.93 and its 200-day moving average is $1.93.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities analysts predict that Catabasis Pharmaceuticals will post ($1.39) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/05/catabasis-pharmaceuticals-inc-catb-earns-outperform-rating-from-cibc.html.

Large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. purchased a new position in Catabasis Pharmaceuticals in the first quarter worth $144,000. Renaissance Technologies LLC purchased a new position in Catabasis Pharmaceuticals in the first quarter worth $106,000. Finally, Virtu KCG Holdings LLC purchased a new position in Catabasis Pharmaceuticals in the second quarter worth $271,000. Hedge funds and other institutional investors own 32.90% of the company’s stock.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.